news aktuell GmbH

MFM Ltd: Roger Waters: We are on the road to Frankfurt


Concert in Frankfurt to be secured by interim injunction

(London, United Kingdom): Roger Waters has noted with pleasure the decision of the Munich City Council that his 21.05.2023 concert in the Olympiahalle Munich will take place as planned:

"I am very happy to be able to perform in Munich for my fans. A ban on my concert would have been illegal. The City of Munich’s decision is good news for freedom of speech in Germany."

Referring to the concert in Frankfurt on 28.05.2023, for which the City of Frankfurt and the State of Hesse are sticking to the cancellation of the contract, Waters went on to say:

"The decision makers in Frankfurt know that they are on the wrong side of the law and are now completely isolated. They should take an example from their colleagues in Munich and instead of wasting a lot of taxpayers’ money on a futile legal action they should follow Munich’s brave example and support freedom in the arts and free speech in general. The cancel attempts of the Frankfurt politicians are an attack on artistic freedom as a whole. Politicians have no right to intimidate and bully artists and their fans with performance bans."

Waters said that he would continue to fight unceasingly for his right to perform in Frankfurt saying:

”I am fighting for all of our human rights, including the right to freedom of speech. We are on the road to Frankfurt. Frankfurt, here we come!

If pre-court efforts fail, Waters' lawyers will seek to secure the performance of the concert in Frankfurt on 28.05.2023 through an interim injunction. Commenting on this intention, Waters said:

“Like all the other concerts on my European tour, my concert in Frankfurt will take place. I will enforce this in court if I must. So my fans don’t have to worry."


HÖCKER Rechtsanwälte PartGmbB
Rechtsanwalt Prof. Dr. Ralf Höcker
Rechtsanwalt Michael Fengler
Tel: +49(0)221-93319-10

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

iTAC Software AG: Closed Loop: Simulating, planning and managing the digital factory24.5.2023 14:48:14 CEST | Press release

The factory of the future is digital and relies on integrated, rather than isolated, solutions. The software companies DUALIS GmbH IT Solution ( and iTAC Software AG ( developed a holistic digitalization approach for greater efficiency, flexibility and quality in manufacturing. In the closed loop model, simulation, APS and MES/MOM are closely interlinked and interact with each other. This means, for example, that manufacturing processes can be optimized end-to-end. At the same time, costs and risks can be minimized.

LONGi publishes its annual report for 2022 and 2023 Q124.5.2023 13:06:07 CEST | Press release

Xi'an, China | Frankfurt, Germany: May 24, 2023 - LONGi Green Energy Technology, a global leading renewable energy company, released its annual report for 2022 and 2023 Q1. According to the financial report, the company achieved a revenue of 128.998 billion yuan in 2022 (USD 19.27 bn), a year-on-year increase of 60.03%. This is the first time that LONGi’s yearly revenue stands above the 100 bn yuan (USD 14.93 bn) level.

Grünenthal’s resiniferatoxin receives Breakthrough Therapy Designation from U.S. FDA for pain associated with osteoarthritis of the knee22.5.2023 10:49:28 CEST | Press release

Knee osteoarthritis is a progressive condition affecting over 360 million people worldwide and may have severe symptoms, including pain. Grünenthal is running a global Phase III programme to investigate the efficacy and safety of intra-articular injections of resiniferatoxin, a non-opioid therapy, in adults with pain associated with knee osteoarthritis. The U.S. Food and Drug Administration’s Breakthrough Therapy Designation process aims to expedite the development of investigational medicines intended to treat severe conditions and where preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on clinically significant endpoints.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom